Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Hexavac

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
In 2005, in accordance with recommendations made by the European Medicines Agency, the Italian Drug Agency ordered withdrawal of… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
2012
2012
BACKGROUND AND AIMS The anamnestic response to a challenge dose of vaccine can assess immune memory and protection against… Expand
Highly Cited
2011
Highly Cited
2011
The immunogenicity of a vaccine is conventionally measured through the level of serum Abs early after immunization, but to ensure… Expand
Highly Cited
2010
Highly Cited
2010
BACKGROUND In 2000, hexavac and infanrix hexa were licensed in Europe for primary immunisation of children against diphtheria… Expand
  • table 1
  • table 3
  • table 2
  • table 4
  • table 5
Highly Cited
2009
Highly Cited
2009
Background:  It has been suggested that human breast milk oligosaccharides play a role in the development of the immune system in… Expand
2008
2008
BackgroundIn 2001, two hexavalent vaccines were licensed in Italy (Hexavac®, Infanrix Hexa®), and since 2002 were extensively… Expand
  • table 1
  • table 2
  • table 3
2006
2006
This study assessed the persistence of antibodies following primary vaccination with two commercially available, hexavalent… Expand
Review
2004
Review
2004
To reduce the number of injections needed to comply with paediatric vaccination requirements, a liquid, hexavalent vaccine (DTaP… Expand
Highly Cited
2000
Highly Cited
2000
Objective. The immunogenicity and safety of a new liquid hexavalent vaccine (diphtheria-tetanus-acellular pertussis-inactivated… Expand
1982
1982
Twenty‐nine patients with extensive disease, small‐cell carcinoma of the lung, were treated with two cycles of intensive… Expand